Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’ Sophie Chansophie.chan@legalease.co.uk9 February 2024ProfileLife Sciences Yearbook 2024 David Gibson, senior associate at McDermott Will & EmeryWhy did you decide to specialise in life sciences law, and what’s the best thing about being a life sciences lawyer?Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Related Content‘Setting ourselves up for the future’ – McDermott ups London trainee pay to £70kMcDermott snaps up CMS international private equity co-head in LondonMcDermott sets sights on big-hitters in London as private client team moves onM&A perspectives: Melissa FogartyM&A perspectives: Jennifer BethlehemM&A perspectives: Lorenzo Corte‘You’d be a brave innovator to ignore the UK’ – why patent work is booming in the post-Brexit UK life sciences marketTaking back control – the post-pandemic landscape for life sciences regulationLife Sciences perspectives: Grant Castle